Evaluation of the Utility of in utero Treatment of Twin Anemia-Polycythemia Sequence
Nicolas Sananès, Marine Veujoz, Francois Severac, Maël Barthoulot, Nicolas Meyer, Anne-Sophie Weingertner, Monique Kohler, Fernando Guerra, Adrien Gaudineau, Israël Nisand, Romain Favre, Nicolas Sananès, Marine Veujoz, Francois Severac, Maël Barthoulot, Nicolas Meyer, Anne-Sophie Weingertner, Monique Kohler, Fernando Guerra, Adrien Gaudineau, Israël Nisand, Romain Favre
Abstract
Objective: The aim of this study is to evaluate the interest in the in utero treatment of twin anemia-polycythemia sequence (TAPS).
Methods: The obstetrical and neonatal data on all cases of TAPS followed up in our institution between 2006 and 2013 were reviewed. Statistical analyses were conducted using Bayesian methods.
Results: Twenty cases of TAPS were included. Laser therapy or intrauterine transfusion (IUT) was performed on the donor twin in 9 cases. Eleven cases were included in the 'nontreated' group (managed expectantly or diagnosed at birth). The gestational age at diagnosis was lower in the group with treated TAPS [difference (diff) = -22.20 days (-57.13, 14.28), probability (Pr) (diff >0) = 10.6%]. The rate of preterm premature rupture of membranes was higher in the group with treated TAPS [diff = 22.5% (-14, 57), Pr (diff >0) = 89%], but overall mortality was similar. The interval between diagnosis and delivery was longer [diff = 44.37 days (9.41, 77.90), Pr (diff >0) = 99.2%], the TAPS resolution rate was higher [diff = 49.9% (12, 81), Pr (diff >0) = 99.4%], and the neonatal transfusion rate was lower [diff = -30.5% (-60, 0), Pr (diff >0) = 2.6%] in the treated group.
Conclusion: In utero treatment for TAPS is associated with a higher resolution rate of TAPS and a longer time between diagnosis and birth, but overall mortality is the same as with expectant management.
© 2015 S. Karger AG, Basel.
Source: PubMed